Endpoints News Mar 23, 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Endpoints News Mar 20, 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News Feb 26, 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News Feb 18, 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News Feb 18, 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News Jan 13, 2026 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News Jan 12, 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Endpoints News Dec 8, 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?